Subscribe to Newsletter to get latest insights & analysis in your inbox. All about ETPharma industry right on your smartphone! Download the ETPharma App and get the Realtime updates and Save your favourite articles. This is expected to significantly accelerate adoption of GLP-1 therapies among diabetics.Market leadership within the GLP-1 segment is likely to remain concentrated among 5-10 players. Dr. Reddy's could emerge as the first Indian generic entrant in Canada, while Sun Pharma may enjoy a first-mover advantage in Brazil.Emerging markets are expected to offer steadier, longer-term growth with comparatively lower regulatory risk.

Source: Economic Times January 05, 2026 03:35 UTC